Prostate cancer: open trials in India

• NCT05348876

  A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

  Trial Treatment · Phase 4 · Bayer

  Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, Amravati · HCG Oncology Center, Bengaluru · All India Institute of Medical Sciences, Bhubaneswar · Jawaharlal Institute Of Postgraduate Medical Education and R, Gorimedu · Apollo Research Foundation, Hyderabad · Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur · Amrita institute of Medical Sciences, Kochi · Netaji Subhas Chandra Bose Cancer Hospital, Kolkata · Tata Memorial Hospital, Mumbai · Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital), Nadiād · Dr. RML Hospital & PGIMER, New Delhi · Rajiv Gandhi Cancer Institute & Research Centre, New Delhi · Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram · Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi · MVR Cancer Centre and Research Institute, Vellalasseri

  Registry updated 2026-11-05

• NCT07806591

  A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

  Research · Bayer

  Many locations, Multiple Locations

  Registry updated 2026-10-20

• NCT07611110

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  Trial Treatment · Phase 3 · AstraZeneca

  Bangalore · Gūrgaon · Navi Mumbai

  Registry updated 2026-10-19

• NCT06855277

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Bengaluru · Gurgaon · Mumbai

  Registry updated 2026-10-15

• NCT07711002

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  Trial Treatment · Phase 3 · AstraZeneca

  Ansārinagar · Bangalore · Delhi · Kannur · Nagpur · New Delhi · Vadodara

  Registry updated 2026-10-15

• NCT06952803

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  Trial Treatment · Phase 3 · AstraZeneca

  Ansārinagar · Babgalore · Calicut · Delhi · Hyderabad · Kannur · Kanpur · Mumbai · Nagpur · Varanasi

  Registry updated 2026-10-14

• NCT07838753

  A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs

  Trial Treatment · Phase 2 · Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute

  Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai

  Registry updated 2026-10-07

• NCT06818682

  Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial

  Trial Treatment · Phase 2 · Tata Memorial Centre

  Tata Memorial Centre, Mumbai

  Registry updated 2025-02-21

All Prostate cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error